Michael Fluck
Internist
Hat mitgewirkt an:
-
Cemiplimab (Libtayo) : die erste zugelassene Therapie beim metastasierten oder lokal fortgeschrittenen kutanen Plattenepithelkarzinom
-
Phase II DeCOG-Study of Ipilimumab in Pretreated and Treatment-Naïve Patients with Metastatic Uveal Melanoma
-
The efficacy of re-challenge with BRAF inhibitors after previous progression to BRAF inhibitors in melanoma : : a retrospective multicenter study
-
The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network